title: EZOGABINE (POTIGA) MACULOPATHY.
abstract: OBJECTIVE
  To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga).
  
  
  METHODS
  Case report with multimodal imaging.
  
  
  METHODS
  A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes.
  
  
  RESULTS
  These macular abnormalities are characterized for the first time with multimodal imaging. They were partially reversible after cessation of the drug.
  
  
  CONCLUSIONS
  Ezogabine toxicity presents as pigmentary changes in the macula on fundus examination and has newly described characteristics on imaging that can guide ophthalmologists when they perform the FDA-recommended 6-month screening visits for ocular toxicity.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah.
authors.forename: Brian E
authors.initials: BE
authors.lastname: Zaugg
authors.forename: James E
authors.initials: JE
authors.lastname: Bell
authors.forename: Kim Y
authors.initials: KY
authors.lastname: Taylor
authors.forename: Paul S
authors.initials: PS
authors.lastname: Bernstein
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D002219:Carbamates / Q000009:adverse effects*; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010655:Phenylenediamines / Q000009:adverse effects*; D012164:Retinal Diseases / Q000139:chemically induced*; D055213:Retinal Pigment Epithelium / Q000473:pathology
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine